Correlation of Antibodies to LAV/HTLV III in Hemophiliacs with the Use of Virus-Inactivated Clotting Factors

Summary

The retrovirus LAV/HTLV III, highly likely to be responsible for the acquired immunodeficiency syndrome (AIDS) in some recipients of blood products, can be inactivated by chemical and/ or heat treatment, so the use of virus-inactivated factor VIII and factor IX preparations for treating hemophilia A and B has become important. We examined hemophilic children and found that those children treated since 1979 with virus-inactivated preparations did not develop antibodies against LAV/HTLV III. In contrast, 77% of patients treated with conventional factor VIII or factor IX preparations had antibodies against this virus.

Keywords

Antibodies to LAV/HTLV III - Virus inactivation - Clotting factors

• References

• 1 Biggs R. Jaundice and antibodies directed against factor VIII and IX in patients treated for hemophilia or Christmas disease in the United Kingdom. Br J Haematol 1974; 26: 313-329
• 2 Alter HJ, Barker LF, Fiedler H, Freywettstein M, Gitnick GL, Greenwalt TJ, Prince AM, Reefink HW, Reinicke V, Seeft LB, Wright EC, Zuckerman AJ. How frequent is posttransfusion hepatitis after the introduction of 3rd generation donor screening for hepatitis B?. What is its probable nature? Vox Sang 1977; 32: 346-363
• 3 Prince AM, Stephan W, Brotman B. β-Propiolactone/ultraviolet irradiation; a review of its effectiveness for inactivation of viruses in blood derivates. Rev Infect Dis 1983; 5: 92-107
• 4 Hoofnagle JH, Gerety RJ, Thiel J, Barker LF. The prevalence of hepatitis B surface antigen in commercially prepared plasma products. J Lab Clin Med 1976; 88: 102-113
• 5 Schimpf K. Hämophilie und Lebererkrankung. Hämostaseologie 1984; 2: 38-43
• 6 Fletcher ML, Trowel JM, Craske J, Pavier K, Rizza CR. Non-A, non-B hepatitis after transfusion of factor VIII in infrequently treated patients. Brit Med J 1983; 287: 1754-1757
• 7 Aach RD, Szmuness W, Mosley JW, Hollinger BF, Kahn RA, Stevens CE, Virginia M, Edwards BS, Werch J. Serum alanine amino-transferase of donors in relation to the risk of non-A, non-B hepatitis in recipients. The transfusion-transmitted viruses study. N Engl J Med 1981; 304: 989-994
• 8 Norkrans G, Widell A, Teger-Nilsson AC, Kjellmann H, Frösner G, Iwarson S. Acute hepatitis non-A, non-B following administration of factor VIII concentrates. Vox Sang 1981; 41: 129-133
• 9 Wyke RJ, Tsiquaye KN, Thornton A, White Y, Portmann B, Das PK, Zuckerman AJ, Williams R. Transmission of non-A, non-B hepatitis to chimpanzees by factor-IX concentrates after fatal complications in patients with chronic liver disease. Lancet 1979; 1: 520-524
• 10 Klose HJ. Hepatitis als Schicksal des Hämophiliepatienten. In: Plasmaproteine und Virushepatitis Frösner G, Lasch HG, Lechler E. (eds), pp. 24-32 Springer; Berlin: 1982
• 11 Barré-Sinoussi F, Chermann JC, Rey F, Nguyère MT, Chamret S, Gruest J, Dauquet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868-871
• 12 Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BS, Palker TJ, Redfield R, Oleske J, Safai B, White G, Foster P, Markham PD. Frequent detection and isolation of cytopathic retroviruses (HTLV III) from patients with AIDS and at risk for AIDS. Science 1984; 224: 500-502
• 13 Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation and continuous production of cytopathic retroviruses (HTLV III) from patients with AIDS and pre-AIDS. Science 1983; 224: 497-500
• 14 Vilmer E, Barré-Sinoussi F, Rouzioux C, Gazengel G, Vezinet-Brun F, Dauguet C, Fischer A, Manigne P, Chermann JC, Griscelli C, Montagnier L. Isolation of new lymphotropic retroviruses from two siblings with haemophilia B, one with AIDS. Lancet 1984; 1: 753-757
• 15 Evatt BL, Gomperts ED, Dougal JS, Ramsey RB. Coincidental appearance of LAV/HTLV III antibodies in hemophiliacs and the onset of the AIDS epidemic. N Engl J Med 1985; 312: 483-486
• 16 Spire B, Dormont D, Barré-Sinoussi F, Montagnier L, Chermann JC. Inactivation of lymphadenopathy-associated virus by heat, gamma rays and ultraviolet light. Lancet 1985; 1: 188-189
• 17 Spire B, Barré-Sinoussi F, Montagnier L, Chermann JC. Inactivation of lymphadenopathy-associated virus by chemical disinfectants. Lancet 1984; 2: 899-901
• 18 Martin LS, McDougal JS, Loskoski SL. Disinfection and inactivation of human T-lymphotropic virus type III/lymphadenopathy-associated virus. J Infect Dis 1985; 152: 400-403
• 19 Ball MJ, Griffiths D. Effect on chemical analyses of beta-propiolactone treatment of whole blood and plasma. Lancet 1985; 1: 1160-1161
• 20 Stephan W, Dichtelmüller H, Kotitschke R, Prince AM, Friis RR, Bauer H. Inaktivierung von NANB-Hepatitisviren und Retroviren in gepooltem Human-plasma durch β-Propiolacton- und UV-Behandlung. In: 29 Jahrestagung der DAB/GTH; Saarbrucken: 1985: 17-18
• 21 Stephan W, Dichtelmüller H, Prince AM. Inactivation of hepatitis viruses and HTLV III in human plasma by means of β-propiolactone and UV for the preparation of virus-safe plasma derivatives. International meeting on Advances in Virology, Catania 15-18 May 1985
• 22 Heimburger N, Schwinn H, Gratz P, Lüben G, Kumpe G, Herchenhau B. Faktor-VIII-Konzentrat, hochgereinigt und in Losung erhitzt. Drug Res 1981; 31: 619-622
• 23 Prince AM, Stephan W, Brotman B. Inactivation of non-A, non-B virus infectivity by a beta-propiolactone/ultraviolet irradiation treatment and aerosil adsorption procedure used for preparation of a stabilized human serum. Vox Sang 1984; 46: 80-85
• 24 Hollinger FB, Dolana G, Thomas W, Gyorkey F. Reduction in risk of hepatitis transmission by heat-treatment of human factor VIII concentrate. J Infect Dis 1984; 150: 250-262
• 25 Wöber G, Dorner F, Eibl J, Elsinger F, Linnau Y, Philapitsch A, Schwarz O. Behandlung von gefriergetrockneten Plasmafraktionen mit heiBem Wasser-dampf. In: 29 Jahrestagung der DAB/GTH; Saarbrucken: 1985: 27-28
• 26 Weiss S, Goedert J, Sarngadharan M, Bodner A, Gallo R, Blattner W. Screening test for HTLV III (AIDS Agent) antibodies. JAMA 1985; 253: 221-225
• 27 Gürtler LG, Wernicke D, Eberle J, Zoulek G, Deinhardt F, Schramm W. Increase in prevalence of anti-HTLV III in haemophiliacs. Lancet 1985; 1: 1275-1276
• 28 Born M, vd Helm K, Wernicke D, Deinhardt F. Presence of antibodies to human lymphoma-leukemia-virus (HTLV I) in Germans with symptoms of the acquired immunodeficiency syndrome (AIDS). J Med Vir 1985; 15: 57-63
• 29 Guroff RM, Ruscetti FW, Posner LE, Poiesz PJ, Gallo RC. Detection of the human T-cell lymphoma virus pl9 in cells of some patients with cutaneous T-cell lymphoma and leukemia using a monoclonal antibody. J Exp Med 1981; 154: 1957-1964
• 30 Rouzioux C, Chamaret S, Montagnier L, Carnelli V, Rolland G, Mannucci PM. Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated factor VIII concentrate. Lancet 1985; 1: 271
• 31 Mösseler J, Schimpf K, Auerswald G, Bayer H, Schneider J, Hunsmann G. Inability of pasteurised factor VIII preparations to induce antibodies to HTLV III after long-term treatment. Lancet 1985; 1: 1111
• 32 Colombo M, Mannucci P, Carnelli V, Savidge GF, Gazengel C, Schimpf K. Transmission of non-A, non-B hepatitis by heat-treated F VIII concentrate. Lancet 1985; 2: 1-3
• 33 Hirsch MS, Wormser GP, Schooley RT, Ho DD, Felsenstein D, Hopkins CC, Joline C, Duncanson F, Sarngadharan MG, Saxinger C, Gallo RC. Risk of nosocomial infection with human T-cell lymphotropic virus III (HTLV III). N Engl J Med 1985; 312: 1-4
• 34 Tsang V CW, Peralta JM, Simons AR. Enzyme-linked immunoelectrotransfer blot techniques (EITB) for studying the specifities of antigens and antibodies separated by gel electrophoresis. Meth Enzym 1983; 92: 377-403